Medicines Co. cardiovascular news

The U.S. Solicitor General declined to appeal a district court decision requiring the U.S. Patent and Trademark Office (PTO) to consider a patent term extension application from The Medicines Co. for anticoagulant Angiomax bivalirudin as timely filed. Last month, the PTO granted a one-year interim extension for the patent after the U.S. District Court for the Eastern District of Virginia issued the ruling (see BioCentury, Aug. 9). ...